JP2020501583A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020501583A5 JP2020501583A5 JP2019533652A JP2019533652A JP2020501583A5 JP 2020501583 A5 JP2020501583 A5 JP 2020501583A5 JP 2019533652 A JP2019533652 A JP 2019533652A JP 2019533652 A JP2019533652 A JP 2019533652A JP 2020501583 A5 JP2020501583 A5 JP 2020501583A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- acid sequence
- amino acid
- antibody
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 90
- 238000004519 manufacturing process Methods 0.000 claims 19
- 239000003814 drug Substances 0.000 claims 18
- 102000003812 Interleukin-15 Human genes 0.000 claims 13
- 108090000172 Interleukin-15 Proteins 0.000 claims 13
- 210000004027 cell Anatomy 0.000 claims 13
- 108010068370 Glutens Proteins 0.000 claims 9
- 235000021312 gluten Nutrition 0.000 claims 9
- 150000007523 nucleic acids Chemical group 0.000 claims 9
- 208000015943 Coeliac disease Diseases 0.000 claims 8
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 claims 8
- 102000004556 Interleukin-15 Receptors Human genes 0.000 claims 8
- 108010017535 Interleukin-15 Receptors Proteins 0.000 claims 8
- 102000056003 human IL15 Human genes 0.000 claims 8
- 206010020751 Hypersensitivity Diseases 0.000 claims 6
- 208000026935 allergic disease Diseases 0.000 claims 6
- 230000009610 hypersensitivity Effects 0.000 claims 6
- 210000000822 natural killer cell Anatomy 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 208000023275 Autoimmune disease Diseases 0.000 claims 5
- 201000007235 gluten allergy Diseases 0.000 claims 5
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 239000013598 vector Substances 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 238000001516 cell proliferation assay Methods 0.000 claims 3
- 238000010494 dissociation reaction Methods 0.000 claims 3
- 230000005593 dissociations Effects 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 210000000813 small intestine Anatomy 0.000 claims 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000010201 Exanthema Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 claims 1
- 206010023791 Large granular lymphocytosis Diseases 0.000 claims 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000021329 Refractory celiac disease Diseases 0.000 claims 1
- 201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000037213 diet Effects 0.000 claims 1
- 235000005911 diet Nutrition 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 206010016766 flatulence Diseases 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 206010037844 rash Diseases 0.000 claims 1
- 231100000046 skin rash Toxicity 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022161059A JP2022176324A (ja) | 2016-12-21 | 2022-10-05 | ヒトｉｌ－１５に特異的に結合する抗体及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437143P | 2016-12-21 | 2016-12-21 | |
| US62/437,143 | 2016-12-21 | ||
| PCT/US2017/067917 WO2018119246A1 (en) | 2016-12-21 | 2017-12-21 | Antibodies that specifically bind to human il-15 and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022161059A Division JP2022176324A (ja) | 2016-12-21 | 2022-10-05 | ヒトｉｌ－１５に特異的に結合する抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020501583A JP2020501583A (ja) | 2020-01-23 |
| JP2020501583A5 true JP2020501583A5 (OSRAM) | 2021-02-04 |
| JP7155126B2 JP7155126B2 (ja) | 2022-10-18 |
Family
ID=62627610
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019533652A Active JP7155126B2 (ja) | 2016-12-21 | 2017-12-21 | ヒトｉｌ－１５に特異的に結合する抗体及びその使用 |
| JP2022161059A Pending JP2022176324A (ja) | 2016-12-21 | 2022-10-05 | ヒトｉｌ－１５に特異的に結合する抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022161059A Pending JP2022176324A (ja) | 2016-12-21 | 2022-10-05 | ヒトｉｌ－１５に特異的に結合する抗体及びその使用 |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US11267883B2 (OSRAM) |
| EP (2) | EP4585261A3 (OSRAM) |
| JP (2) | JP7155126B2 (OSRAM) |
| KR (2) | KR102706743B1 (OSRAM) |
| CN (1) | CN110234349B (OSRAM) |
| AR (1) | AR110414A1 (OSRAM) |
| AU (2) | AU2017382850B2 (OSRAM) |
| BR (1) | BR112019012570A8 (OSRAM) |
| CA (1) | CA3046387A1 (OSRAM) |
| CL (1) | CL2019001729A1 (OSRAM) |
| DK (1) | DK3558369T3 (OSRAM) |
| EA (1) | EA201991514A1 (OSRAM) |
| ES (1) | ES3026508T3 (OSRAM) |
| FI (1) | FI3558369T3 (OSRAM) |
| HR (1) | HRP20250482T1 (OSRAM) |
| HU (1) | HUE071878T2 (OSRAM) |
| IL (1) | IL267113B2 (OSRAM) |
| LT (1) | LT3558369T (OSRAM) |
| MA (1) | MA47130B1 (OSRAM) |
| MD (1) | MD3558369T2 (OSRAM) |
| MX (2) | MX2019007357A (OSRAM) |
| PE (1) | PE20191497A1 (OSRAM) |
| PH (1) | PH12019501453A1 (OSRAM) |
| PL (1) | PL3558369T3 (OSRAM) |
| PT (1) | PT3558369T (OSRAM) |
| RS (1) | RS66900B1 (OSRAM) |
| SI (1) | SI3558369T1 (OSRAM) |
| UA (1) | UA126284C2 (OSRAM) |
| WO (1) | WO2018119246A1 (OSRAM) |
| ZA (1) | ZA201903848B (OSRAM) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI707038B (zh) | 2013-08-05 | 2020-10-11 | 美商扭轉生物科技有限公司 | 重新合成之基因庫 |
| WO2016126882A1 (en) | 2015-02-04 | 2016-08-11 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
| US9981239B2 (en) | 2015-04-21 | 2018-05-29 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
| HK1258869A1 (zh) | 2015-09-18 | 2019-11-22 | Twist Bioscience Corporation | 寡核酸变体文库及其合成 |
| CN108698012A (zh) | 2015-09-22 | 2018-10-23 | 特韦斯特生物科学公司 | 用于核酸合成的柔性基底 |
| US10417457B2 (en) | 2016-09-21 | 2019-09-17 | Twist Bioscience Corporation | Nucleic acid based data storage |
| AU2017382850B2 (en) | 2016-12-21 | 2024-11-21 | Cephalon Llc | Antibodies that specifically bind to human IL-15 and uses thereof |
| US11550939B2 (en) | 2017-02-22 | 2023-01-10 | Twist Bioscience Corporation | Nucleic acid based data storage using enzymatic bioencryption |
| IL271205B2 (en) | 2017-06-12 | 2025-02-01 | Twist Bioscience Corp | Methods for assembling continuous nucleic acids |
| WO2018231864A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
| GB2581620A (en) | 2017-09-11 | 2020-08-26 | Twist Bioscience Corp | GPCR binding proteins and synthesis thereof |
| CA3079613A1 (en) | 2017-10-20 | 2019-04-25 | Twist Bioscience Corporation | Heated nanowells for polynucleotide synthesis |
| GB2585506A (en) | 2018-01-04 | 2021-01-13 | Twist Bioscience Corp | DNA-based digital information storage |
| CA3100739A1 (en) | 2018-05-18 | 2019-11-21 | Twist Bioscience Corporation | Polynucleotides, reagents, and methods for nucleic acid hybridization |
| JP2021530243A (ja) | 2018-07-25 | 2021-11-11 | アスクジーン・ファーマ・インコーポレイテッドAskGene Pharma, Inc. | 新規ｉｌ−２１プロドラッグおよびそれを使用する方法 |
| US11828385B2 (en) | 2018-12-25 | 2023-11-28 | Ntn Corporation | Flow control valve seal and flow control valve device |
| EP3902816A4 (en) | 2018-12-26 | 2022-09-14 | Twist Bioscience Corporation | HIGHLY ACCURATE POLYNUCLEOTIDE DE NOVO SYNTHESIS |
| AU2020227802A1 (en) | 2019-02-26 | 2021-10-14 | Twist Bioscience Corporation | Variant nucleic acid libraries for antibody optimization |
| JP2022521551A (ja) | 2019-02-26 | 2022-04-08 | ツイスト バイオサイエンス コーポレーション | Ｇｌｐ１受容体の変異体核酸ライブラリ |
| WO2020252264A1 (en) | 2019-06-12 | 2020-12-17 | AskGene Pharma, Inc. | Novel il-15 prodrugs and methods of use thereof |
| AU2020298294A1 (en) | 2019-06-21 | 2022-02-17 | Twist Bioscience Corporation | Barcode-based nucleic acid sequence assembly |
| US12091777B2 (en) | 2019-09-23 | 2024-09-17 | Twist Bioscience Corporation | Variant nucleic acid libraries for CRTH2 |
| EP4034564A4 (en) | 2019-09-23 | 2023-12-13 | Twist Bioscience Corporation | VARIANT NUCLEIC ACID LIBRARIES FOR SINGLE-DOMAIN ANTIBODIES |
| US20210179724A1 (en) * | 2019-12-09 | 2021-06-17 | Twist Bioscience Corporation | Variant nucleic acid libraries for adenosine receptors |
| WO2022082201A1 (en) * | 2020-10-16 | 2022-04-21 | Genentech, Inc. | Anti-cleaved icaspase substrate antibodies and methods of use |
| WO2022159620A1 (en) | 2021-01-21 | 2022-07-28 | Twist Bioscience Corporation | Methods and compositions relating to adenosine receptors |
| CN116655771A (zh) * | 2021-05-28 | 2023-08-29 | 苏州复融生物技术有限公司 | 一种新型白介素15突变体多肽的开发及其应用 |
| WO2024028448A1 (en) | 2022-08-04 | 2024-02-08 | Calypso Biotech Sa | Il-15 inhibitors useful for the treatment of atopic dermatitis |
| CN118894934A (zh) * | 2023-05-05 | 2024-11-05 | 北京智仁美博生物科技有限公司 | 抗人il-15的抗体及其用途 |
| CN117209605B (zh) * | 2023-11-09 | 2024-01-30 | 北京百普赛斯生物科技股份有限公司 | 特异性结合il-15的抗体及其应用 |
| WO2025227052A1 (en) | 2024-04-26 | 2025-10-30 | Cephalon Llc | Doses and formulations of anti-il-15 antibody for the treatment of immune diseases |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5795966A (en) * | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
| KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| DK1355919T3 (da) | 2000-12-12 | 2011-03-14 | Medimmune Llc | Molekyler med længere halveringstider, sammensætninger og anvendelser deraf |
| US7132510B2 (en) * | 2000-12-29 | 2006-11-07 | Bio-Technology General (Israel) Ltd. | Specific human antibodies for selective cancer therapy |
| US7329405B2 (en) * | 2001-08-23 | 2008-02-12 | Genmab A/S | Human antibodies specific for interleukin 15 (IL-15) |
| US7247304B2 (en) * | 2001-08-23 | 2007-07-24 | Genmab A/S | Methods of treating using anti-IL-15 antibodies |
| WO2003017935A2 (en) | 2001-08-23 | 2003-03-06 | Genmab A/S | Human antibodies specific for interleukin 15 (il-15) |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| MXPA05005921A (es) | 2002-12-02 | 2005-10-19 | Abgenix Inc | Anticuerpos dirigidos a factor de necrosis tumoral y sus usos. |
| JP4892335B2 (ja) * | 2003-02-26 | 2012-03-07 | ゲンマブ エー／エス | インターロイキン１５（ｉｌ−１５）に特異的なヒト抗体 |
| AR050293A1 (es) * | 2004-08-11 | 2006-10-11 | Moll Tomas | Polipeptidos de interleuquina-15 mutante |
| WO2006090750A1 (ja) | 2005-02-28 | 2006-08-31 | Institute For Antibodies Co., Ltd. | 抗IgSF4抗体及びその利用 |
| EP2418278A3 (en) * | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| SG182144A1 (en) | 2007-06-01 | 2012-07-30 | Omt Inc | Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies |
| AR068767A1 (es) * | 2007-10-12 | 2009-12-02 | Novartis Ag | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina |
| ES2948572T3 (es) | 2009-07-08 | 2023-09-14 | Kymab Ltd | Modelos de roedores y moléculas terapéuticas |
| AR078650A1 (es) * | 2009-10-15 | 2011-11-23 | Abbott Lab | Anticuerpo de union a il-1 beta |
| EP2550529B1 (en) * | 2010-03-23 | 2021-11-17 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
| US9127057B2 (en) * | 2010-07-20 | 2015-09-08 | Teva Pharmaceuticals Ausralia Pty Ltd | Anti-IL-23 heterodimer specific antibodies |
| JP5820688B2 (ja) | 2011-03-23 | 2015-11-24 | 株式会社Kri | 多糖類の溶解に用いられる溶媒ならびに該溶媒を用いた成形体および多糖類誘導体の製造方法 |
| CN103890006A (zh) | 2011-08-23 | 2014-06-25 | 罗切格利卡特公司 | 抗mcsp抗体 |
| KR102096224B1 (ko) * | 2011-10-28 | 2020-04-03 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | 폴리펩티드 구축물 및 이의 용도 |
| MX2015010350A (es) * | 2013-02-26 | 2015-10-29 | Roche Glycart Ag | Moleculas de union a antigeno biespecificas que activan la celula t. |
| UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
| EP2963057A1 (en) | 2014-07-02 | 2016-01-06 | Calypso Biotech SA | Antibodies to IL-15 |
| HUE053097T2 (hu) | 2015-03-31 | 2021-06-28 | Medimmune Ltd | Új IL33 forma, IL33 mutáltatott formái, ellenanyagok, vizsgálati eljárások és eljárások azok alkalmazására |
| EP3472202A1 (en) | 2016-06-15 | 2019-04-24 | Amgen Inc. | Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease |
| CA3040504A1 (en) | 2016-10-14 | 2018-04-19 | Xencor, Inc. | Il15/il15ra heterodimeric fc-fusion proteins |
| AU2017382850B2 (en) | 2016-12-21 | 2024-11-21 | Cephalon Llc | Antibodies that specifically bind to human IL-15 and uses thereof |
-
2017
- 2017-12-21 AU AU2017382850A patent/AU2017382850B2/en active Active
- 2017-12-21 RS RS20250577A patent/RS66900B1/sr unknown
- 2017-12-21 LT LTEPPCT/US2017/067917T patent/LT3558369T/lt unknown
- 2017-12-21 EP EP25165676.5A patent/EP4585261A3/en active Pending
- 2017-12-21 IL IL267113A patent/IL267113B2/en unknown
- 2017-12-21 PT PT178838009T patent/PT3558369T/pt unknown
- 2017-12-21 HU HUE17883800A patent/HUE071878T2/hu unknown
- 2017-12-21 JP JP2019533652A patent/JP7155126B2/ja active Active
- 2017-12-21 PL PL17883800.9T patent/PL3558369T3/pl unknown
- 2017-12-21 WO PCT/US2017/067917 patent/WO2018119246A1/en not_active Ceased
- 2017-12-21 KR KR1020237031493A patent/KR102706743B1/ko active Active
- 2017-12-21 KR KR1020197019269A patent/KR20190097094A/ko not_active Abandoned
- 2017-12-21 BR BR112019012570A patent/BR112019012570A8/pt unknown
- 2017-12-21 CA CA3046387A patent/CA3046387A1/en active Pending
- 2017-12-21 FI FIEP17883800.9T patent/FI3558369T3/fi active
- 2017-12-21 HR HRP20250482TT patent/HRP20250482T1/hr unknown
- 2017-12-21 MD MDE20191253T patent/MD3558369T2/ro unknown
- 2017-12-21 MX MX2019007357A patent/MX2019007357A/es unknown
- 2017-12-21 MA MA47130A patent/MA47130B1/fr unknown
- 2017-12-21 EA EA201991514A patent/EA201991514A1/ru unknown
- 2017-12-21 CN CN201780079926.6A patent/CN110234349B/zh active Active
- 2017-12-21 SI SI201731602T patent/SI3558369T1/sl unknown
- 2017-12-21 UA UAA201908753A patent/UA126284C2/uk unknown
- 2017-12-21 US US16/471,616 patent/US11267883B2/en active Active
- 2017-12-21 DK DK17883800.9T patent/DK3558369T3/da active
- 2017-12-21 ES ES17883800T patent/ES3026508T3/es active Active
- 2017-12-21 AR ARP170103614A patent/AR110414A1/es unknown
- 2017-12-21 EP EP17883800.9A patent/EP3558369B1/en active Active
- 2017-12-21 PE PE2019001283A patent/PE20191497A1/es unknown
-
2019
- 2019-06-13 ZA ZA2019/03848A patent/ZA201903848B/en unknown
- 2019-06-19 MX MX2023014081A patent/MX2023014081A/es unknown
- 2019-06-20 CL CL2019001729A patent/CL2019001729A1/es unknown
- 2019-06-21 PH PH12019501453A patent/PH12019501453A1/en unknown
-
2022
- 2022-01-05 US US17/647,082 patent/US12410247B2/en active Active
- 2022-10-05 JP JP2022161059A patent/JP2022176324A/ja active Pending
-
2025
- 2025-02-20 AU AU2025201185A patent/AU2025201185A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020501583A5 (OSRAM) | ||
| RU2474588C2 (ru) | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения | |
| FI3558369T3 (fi) | Spesifisesti ihmisen il-15:een sitoutuvia vasta-aineita ja niiden käyttötapoja | |
| KR101982899B1 (ko) | ＴＬ1ａ에 대한 항체 및 그의 용도 | |
| RU2577228C2 (ru) | Анти-il-17-антитела, способ их получения и способ применения | |
| ES2319866T3 (es) | Anticuerpos de especificidad dual y metodos de fabricacion y uso. | |
| JP2018537962A5 (OSRAM) | ||
| RU2012130840A (ru) | Соединения | |
| JP2010526028A5 (OSRAM) | ||
| RU2014147773A (ru) | Человеческие антитела с высокой аффинностью к рецепторам il-4 человека | |
| RU2010132647A (ru) | Анти-mif антитела | |
| CN101512008A (zh) | 白介素-13结合蛋白 | |
| SI2481753T1 (en) | Anti-IL-17 antibodies | |
| JP2013543384A5 (OSRAM) | ||
| RU2009140313A (ru) | АНТИТЕЛА ПРОТИВ IgE | |
| JP2011527579A (ja) | プロスタグランジンｅ２結合タンパク質およびこの使用 | |
| KR20130080058A (ko) | Ｉｌ-12/ｐ40 결합 단백질 | |
| ME00519B (me) | Antitijela visokog afiniteta prema humanom il-6 receptoru | |
| WO2011127141A1 (en) | TNF-α BINDING PROTEINS | |
| JP2011520898A5 (OSRAM) | ||
| JP2021500916A5 (OSRAM) | ||
| RU2011116927A (ru) | Антитела против интерлейкина 17 (ил-17) человека и их применение | |
| WO2008079361A2 (en) | Cxcl13 binding proteins | |
| TW201031421A (en) | IL-1 binding proteins | |
| RU2007133608A (ru) | Моноклональные антитела против интерферона-альфа и способы применения |